Degenerative disease destroys essential cells.
CiRC replaces them.
CiRC creates replacements for essential cells lost to degenerative disease. Our platform directly converts fibroblasts into functional neurons without genetic modification. The process is designed to be commercially scalable from early development, without the manufacturing complexity that stem cell-based approaches require.
Degenerative disease destroys essential cells.
CiRC replaces them.
CiRC creates replacements for essential cells lost to degenerative disease. Our platform directly converts fibroblasts into functional neurons without genetic modification. The process is designed to be commercially scalable from early development, without the manufacturing complexity that stem cell-based approaches require.
Degenerative disease destroys essential cells.
CiRC replaces them.
CiRC creates replacements for essential cells lost to degenerative disease. Our platform directly converts fibroblasts into functional neurons without genetic modification. The process is designed to be commercially scalable from early development, without the manufacturing complexity that stem cell-based approaches require.
Direct reprogramming, without stem cells.
CiRC’s platform directly converts fibroblasts into target cells through direct reprogramming. It does not involve pluripotent stem cells at any stage, eliminating tumorigenic risk and expansion steps that add complexity and variability to stem cell–based approaches.
A process built for scale.
Simple and efficient fibroblast conversion process using standard techniques, materials and equipment available at established cell therapy facilities. This enables a clear path to scalable commercialization and supply of large patient populations at low cost.
Direct reprogramming, without stem cells.
CiRC's platform directly converts fibroblasts into target cells through direct reprogramming. It does not involve pluripotent stem cells at any stage, eliminating tumorigenic risk and expansion steps that add complexity and variability to stem cell–based approaches.
A process built for scale.
Simple and efficient fibroblast conversion process using standard techniques, materials and equipment available at established cell therapy facilities. This enables a clear path to scalable commercialization and supply of large patient populations at low cost.
Direct reprogramming, without stem cells.
CiRC's platform directly converts fibroblasts into target cells through direct reprogramming. It does not involve pluripotent stem cells at any stage, eliminating tumorigenic risk and expansion steps that add complexity and variability to stem cell–based approaches.
A process built for scale.
Simple and efficient fibroblast conversion process using standard techniques, materials and equipment available at established cell therapy facilities. This enables a clear path to scalable commercialization and supply of large patient populations at low cost.
Pipeline
Pipeline
Pipeline
